Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: dates

Bioavailability and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas

P. Cassier et al. ESMO 2021 Download the poster here Poster Presentation

Published 16 September 2021
Categorized as -others, 2021, Publication, TG6002

Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002

Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002

Published 16 September 2021
Categorized as 2021, Press release, TG6002

Transgene Announces Upcoming Investor Meetings

Transgene Announces Upcoming Investor Meetings

Published 13 September 2021
Categorized as 2021, News, News-fr-en, Press release

Transgene Participates in New Cancer Research Consortium

Transgene Participates in New Cancer Research Consortium

Published 1 September 2021
Categorized as 2021, Press release, Invir.IO, Press release, TG4001, TG4001

3D organoids derived from patients’ lung tumors: a tool for investigating the potential of oncolytic viruses

Poster BT-001 Hélène Lê et al. EUROoCS 2021 Download the Poster here Poster Presentation

Published 1 July 2021
Categorized as -others, -others, 2021, BT-001, Publication, TG6002

First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy

First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy

Published 28 June 2021
Categorized as 2021, dates, Myvac, Press release, TG4050

First patient enrolled in expanded Phase II clinical trial of TG4001 + avelumab vs avelumab alone in patients with HPV16-positive anogenital cancers

20210624 Transgene TG4001.12 FPI EN

Published 24 June 2021
Categorized as 2021, Press release, TG4001, TG4001

Transgene announces the success of its Capital Increase via a Private Placement

20210622 – Transgene – Pricing PR – ENG – V DEF website

Published 22 June 2021
Categorized as 2021, Press release

Transgene Launches a Capital Increase via a Private Placement

Transgene – Launch CP – ENG – website

Published 21 June 2021
Categorized as 2021, Press release

Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors (ICIs)

20210608 – IP Invir.IO ICI – EN

Published 8 June 2021
Categorized as 2021, Invir.IO, Press release

Posts pagination

Newer posts Page 1 … Page 20 … Page 47 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu